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unusual circumstances such as uveitic cataracts or some
patients with trauma. This study provides support for
that dosing choice since postoperative inﬂammation was
adequately controlled in even our youngest enrollees.
Infants less than 7 months of age were routinely left
aphakic. Although it is true that some surgeons in the
Infant Aphakia Treatment Study (IATS) used steroid
drops more frequently than four times per day, the rate of
inﬂammatory complications was not lower in those dosed
more than four times per day.2 We can make no statement
about the use of diﬂuprednate more frequently than four
times per day, but our study demonstrated good control
of postoperative inﬂammation at that dosage and no
increase in adverse events when compared with
prednisolone acetate, the current standard.
The centers in our study were chosen, in part, because
they were experienced and routinely successful at
checking intraocular pressure in infants and small
children. The Icare (Finland) rebound tonometer has
become a popular device among pediatric cataract
surgeons in the USA for measuring IOP in this age group
without sedation pediatric cataract surgeons in the USA
and it was used in this study.3 Both pre-surgery IOP and
post-operative IOP readings were taken in a clinical area
outside of the operating room. Our study IOP readings
were not done under general anesthesia.
Since the IATS recommended that most infants under
7 months of age be left aphakic and treated with a contact
lens, infants treated in this manner were enrolled and
randomized in our study.4 Extended-wear silicone contact
lenses or daily-wear rigid gas permeable contact lenses
were used. With these materials (0% water content),
we found no adverse events related to placing the drops
on the eye while the contact lens was being worn. It is
likely that the package insert advising against the
instillation of topical diﬂuprednate while wearing contact
lens is for high water content contact lenses that are
not available in the powers needed to correct aphakic
infants.
Drug choice and dosing in infants and young children
after cataract surgery will remain a personal choice of the
surgeon. Our study provides evidence that diﬂuprednate
can be safely used at QID dosing in children aged
0–3 years.
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Sir,
Two-year outcomes of intravitreal bevacizumab for
choroidal neovascularization associated with a
dome-shaped macula in pathologic myopia
A dome-shaped macula (DSM) is an inward protrusion
of the macula seen on optical coherence tomography
(OCT) in highly myopic eyes, which was ﬁrst described
in 2008 by Gaucher et al.1 Since DSM appears to be a
distinct feature of highly myopic eyes,2,3 it could be
suspected that choroidal neovascularization (CNV) that
develops in myopic eyes with DSM may have different
clinical features and may follow a course different from
that of CNV found in myopic eyes without DSM.
However, studies on the therapeutic outcome of CNV
associated with DSM are limited. When searching
PubMed using the keyword ‘dome-shaped macula’,
only one brief report that showed the visual outcome of
myopic CNV with DSM after 1-year intravitreal
ranibizumab treatment was identiﬁed.3 The purpose of
this study was to determine the 2-year visual and
anatomical outcomes of intravitreal bevacizumab (IVB)
treatment for myopic CNV with DSM features. The
secondary objective was to compare patients with
and without DSM, to investigate whether there was any
difference in the clinical features and therapeutic
outcome in these two groups after IVB treatment.
We retrospectively reviewed the medical records of 50
patients with myopic CNV who received IVB injections
between 1 January 2009 and 30 April 2014. Inclusion
criteria were as follows: (1) a refractive error ≤− 6.0 D or
an axial length ≥ 26.5 mm, (2) the presence of subfoveal,
juxtafoveal, or extrafoveal CNV, (3) treatment-naive
patients who were treated with at least one IVB, and
(4) follow-up of 2 years or more after intravitreal injection.
The study was approved by the institutional review
board of Yonsei University College of Medicine. After the
initial IVB at baseline, retreatments were applied pro re
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nata on the basis of changes in OCT ﬁndings and/or
changes in visual acuity. Statistical analysis was
performed using SPSS version 20.0 (IBM, Chicago,
IL, USA).
Out of 50 eyes with myopic CNV, 9 (18%) eyes
showed DSM features. The demographics and
clinical characteristics of patients with and without
DSM are summarized in Table 1. The eyes with myopic
CNV associated with DSM received 4.00± 3.04
injections during 2 years, and the recurrence rate
over the 2-year period was 33.3%. The mean logMAR
best-corrected visual acuity in eyes with DSM
signiﬁcantly improved from 1.20 at baseline to
0.80 at 6 months, 0.76 at 1 year, and 0.72 at 2 years
(P= 0.048, 0.034, 0.011, respectively). Both retinal and
choroidal thickness decreased gradually over
2 years. There was no signiﬁcant difference
between the DSM and the non-DSM group in terms of
baseline characteristics and therapeutic outcomes,
including number of injections and CNV
recurrence. Visual outcomes were also comparable
between the two groups at 6 months, 1 year, and 2 years
(Figure 1).
In conclusion, DSM features were present in 18% of
myopic CNV patients, and after a 2-year treatment with
IVB, myopic CNV patients both with and without DSM
showed equally signiﬁcant visual beneﬁts and
anatomical improvements. The development of CNV in
patients with DSM may not be associated with DSM
features, but with other more signiﬁcant factors, such as
myopia itself.
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Table 1 Demographics and clinical characteristics of patients
with and without dome-shaped macula
DSM Non-DSM P-value
Number of patients (%) 9 (18%) 41 (82%)
Age (years) 59.00± 11.33 50.88± 15.19 0.138
Sex (male/female) 2/7 7/34 1.000
Refractive error (D) − 13.21± 4.02 − 10.74± 3.90 0.144
Baseline BCVA (logMAR) 1.20± 0.71 0.93± 0.66 0.281
2-year BCVA (logMAR) 0.72± 0.64 0.72± 0.66 0.974
CNV location
(subfoveal/non-subfoveal)
4/5 28/13 0.253
CNV area (mm2) 0.49± 0.35 0.46± 0.45 0.892
Subfoveal retinal thickness (μm)
Baseline 258.50± 106.80 332.58± 106.05 0.184
6 months 186.14± 78.07 253.10± 104.47 0.172
1-year 189.43± 75.52 261.67± 91.09 0.090
2-year 183.57± 71.28 271.46± 105.26 0.067
Subfoveal choroidal thickness (μm)
Baseline 66.44± 36.53 102.22± 73.33 0.174
6 months 54.13± 27.60 90.52± 57.12 0.055
1-year 49.67± 22.05 86.77± 57.55 0.051
2-year 49.56± 26.83 82.23± 66.10 0.188
CNV recurrence (%) 33.3 34.1 0.705
Number of injections 4.00± 3.04 4.90±3.48 0.475
Chorioretinal atrophy
progression (%)
11.1 34.1 0.247
Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal
neovascularization.
Figure 1 Visual outcome during the follow-up period after
intravitreal bevacizumab treatment in patients with and without
a dome-shaped macula. There was no difference between the 2
groups at 6 months, 1 year, and 2 years.
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